专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2009242423A Coated particle, its production method and using method 审中-公开
标题翻译：包覆颗粒，其生产方法和使用方法
公开(公告)号：JP2009242423A
公开(公告)日：2009-10-22
申请号：JP2009164832
申请日：2009-07-13
申请人： Lyotropic Therapeutics Inc , リオトロピックセラピュティックスアイエヌシー.
发明人： ANDERSON DAVID M
IPC分类号： A61K9/14 , A61K31/085 , A01N25/26 , A01N25/28 , A01N65/00 , A61K9/10 , A61K9/127 , A61K31/165 , A61K31/167 , A61K31/20 , A61K31/337 , A61K31/56 , A61K31/7088 , A61K31/715 , A61K38/00 , A61K38/22 , A61K39/395 , A61K45/00 , A61K47/10 , A61K47/24 , A61K47/26 , A61K47/30 , A61K47/34 , A61K47/36 , A61K47/42 , A61K47/44 , A61K49/04 , A61P5/14 , A61P9/12 , A61P23/02 , A61P25/00 , A61P29/00 , A61P35/00 , B01J13/02 , B01J13/14 , B01J19/00 , B32B9/02 , B32B15/04 , B32B19/00 , B32B27/00 , C08J3/12 , C08L101/00 , C09B67/08
CPC分类号： A61K9/1274 , A01N25/26 , A61K9/501 , A61K9/5015 , B01J13/02 , Y10T428/2984 , Y10T428/2989 , Y10T428/31544
摘要： PROBLEM TO BE SOLVED: To provide a reverse cubic crystal phase material or a reverse hexagonal crystal phase material, which brings a wide range of various materials including those liable to physically, chemically or biologically deteriorate into solubilizing materials, or is used for a coated particle suitable for containing them. SOLUTION: The reverse cubic crystal phase material or reverse hexagonal crystal phase material, comprises water, glycerol or a mixture of water with glycerol, an anesthetic and a surfactant selected from the group consisting of fluorine based surfactants, BRIJ type surfactants, TRITON type surfactants, polymer chain-having surfactants, peptide based surfactants, isoprenoids, plasminogens, cerebrosides, sulfatides, gangliosides, cyclopentane-triol lipids, dimethylamino propane lipids, lysolipids, lysolecithins, anionic surfactants, cationic surfactants, zwitterionic or semipolar surfactants, benzalkonium chloride, sodium deoxycholate, myristyl chloride-γ-picolinium, polyoxyl 35 castor oil, sorbitan monopalmitate and sodium 2-ethylhexanoate. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：要解决的问题：为了提供反向立方晶相材料或反六方晶相材料，其带来各种各样的材料，包括易于物理，化学或生物降解成增溶材料的各种材料，或用于适合容纳它们的涂覆颗粒。解决方案：反相立方晶相材料或反六方晶相材料包括水，甘油或水与甘油的混合物，麻醉剂和选自氟基表面活性剂，BRIJ型表面活性剂，TRITON 表面活性剂，含聚合物链的表面活性剂，基于肽的表面活性剂，类异戊二烯，纤溶酶原，脑苷脂，硫苷脂，神经节苷脂，环戊烷 - 三醇脂质，二甲基氨基丙烷脂质，溶脂体，溶血卵磷脂，阴离子表面活性剂，阳离子表面活性剂，两性离子或半极性表面活性剂，苯扎氯铵，脱氧胆酸钠，肉豆蔻酰氯-γ-吡啶鎓，聚氧乙烯35蓖麻油，脱水山梨糖醇单棕榈酸酯和2-乙基己酸钠。版权所有（C）2010，JPO＆INPIT

2. 发明申请

WO2006113462A3 FORMULATIONS OF QUATERNARY AMMONIUM NEUROMUSCULAR BLOCKING AGENTS 审中-公开
标题翻译：四甲氨喋呤神经阻滞剂的制剂
公开(公告)号：WO2006113462A3
公开(公告)日：2006-12-07
申请号：PCT/US2006014121
申请日：2006-04-14
申请人： LYOTROPIC THERAPEUTICS INC
发明人： ANDERSON DAVID M
IPC分类号： A61K31/56 , A61K31/425 , A61K31/60
CPC分类号： A61K45/06 , A61K9/0019 , A61K9/1274 , A61K31/14 , A61K31/58 , A61K47/24 , A61K2300/00
摘要： Muscle relaxant formulations which include one or more quaternary ammonium neuromuscular blocking agents have a reduced tendency for hydrolytic degradation, and therefore a longer shelf life stability, when combined with one or more organic anions having at least six carbon atoms and having a pKa of less than 4.0 (preferably ranging from 0.5 to 3.5). Particularly good results are achieved when using acids of very low solubility in water, such as gentisic acid which is less than 1% soluble at room temperature.
摘要翻译：包含一种或多种季铵神经肌肉阻滞剂的肌肉松弛剂制剂当与一种或多种具有至少6个碳原子并且pKa小于1的有机阴离子组合时具有降低的水解降解趋势，因此具有更长的保质期稳定性 4.0（优选为0.5〜3.5）。当在水中使用非常低的溶解度的酸如在室温下小于1％可溶的龙胆酸时，可以获得特别好的结果。

3. 发明申请

WO2006041878A3 PRIMARY EXAMINER 审中-公开
公开(公告)号：WO2006041878A3
公开(公告)日：2006-04-20
申请号：PCT/US2005/035752
申请日：2005-10-06
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David , CAMERANSI, Benjamin, G., Jr.
IPC分类号： A61K31/4453 , A61K9/107
摘要： Drug formulations that provide sustained action and/or reduced dosage requirements are provided. In the formulations the drugs (particularly local anesthetics) are associated with reversed cubic phase and reversed hexagonal phase lyotropic liquid crystalline material.

4. 发明申请

WO2004012680A2 LIPID-DRUG COMPLEXES IN REVERSED LIQUID AND LIQUID CRYSTALLINE PHASES 审中-公开
标题翻译：反相液相和液晶相中的脂质 - 药物复合物
公开(公告)号：WO2004012680A2
公开(公告)日：2004-02-12
申请号：PCT/US2003/024512
申请日：2003-08-06
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M.
IPC分类号： A61K
CPC分类号： A61K9/1274 , A61K47/541 , A61K47/55
摘要： A pharmaceutical is formulated to enable enhanced delivery across membrane barriers, permit solubilization, protect compounds from deactivation by thiol containing compounds in the body, and allow retention of the drug during transport to a desired site of activity. The pharmaceutical includes a complex of two moieties where at least one is pharmaceutically active and is larger than a single atom in size, and the second moiety, when combined with a cationic or anionic counterion forms either a pharmaceutically acceptable anionic or cationic surfactant or a pharmaceutically acceptable salt that has an octanol water partition coefficient of greater than about 100.
摘要翻译：配制药物以增强穿过膜屏障的递送，允许溶解，保护化合物免受体内含硫醇化合物的失活，并允许药物在运输至期望的活性部位期间保留。药物包括两个部分的复合物，其中至少一个具有药学活性并且大于单个原子的大小，并且当第二部分与阳离子或阴离子平衡离子结合时形成药学上可接受的阴离子或阳离子表面活性剂或药学上可接受的辛醇水分配系数大于约100的可接受盐。

5. 发明申请

WO2003106589A1 A NANOPOROUS PARTICLE WITH A RETAINED TARGET 审中-公开
标题翻译：具有保留目标的纳米颗粒
公开(公告)号：WO2003106589A1
公开(公告)日：2003-12-24
申请号：PCT/US2002/018657
申请日：2002-06-13
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M.
IPC分类号： C09K19/00
CPC分类号： B82Y5/00 , C09K19/00 , C12Q1/68 , G01N33/5436 , C12Q2565/629
摘要： Porous nanostructured materials, such as porous nanostructured liquid and liquid crystalline particles or materials, incorporate a target substantially within the material which selectively binds a chemical of interest which can diffusion within the porous nanostructured material and be bound by the target. The porous nanostructured materials can be dispersed as particles in a medium in which said chemical of interest is located with low turbidity. Markers which detect binding of said chemical of interest can be maintained in the medium separate and apart from the target, and any active compound (e.g., an enzyme) associated therewith by the porous nanostructured material, such that detectable changes in the maker only result when the active compounds diffuse out of the porous nanostructured materials after the chemical of interest binds to the target.
摘要翻译：多孔纳米结构材料，例如多孔纳米结构化液体和液晶颗粒或材料，将基本上在目标物质内的目标物结合的材料中，靶材料选择性地结合目的化学物质，其可在多孔纳米结构化材料内扩散。多孔纳米结构材料可以作为颗粒分散在所述感兴趣的化学物质位于低浊度的介质中。检测所述化学物质的结合的标记物可以在分离和分离靶的培养基以及与多孔纳米结构材料相关联的任何活性化合物（例如，酶）中保持，使得制造商的可检测变化仅在感兴趣的化学物质结合靶之后，活性化合物从多孔纳米结构材料中扩散出来。

6. 发明申请

WO2005013919A3 TREATMENT USING DANTROLENE 审中-公开
标题翻译：使用DANTROLENE治疗
公开(公告)号：WO2005013919A3
公开(公告)日：2006-05-18
申请号：PCT/US2004006135
申请日：2004-03-01
申请人： LYOTROPIC THERAPEUTICS INC
发明人： ANDERSON DAVID , CAMERANSI BENJAMIN G , CONKLIN VINCENT M
IPC分类号： A61K20060101 , A61K6/00 , A61K9/127 , A61K9/14 , A61K31/4166 , A61K31/415
CPC分类号： A61K31/415 , A61K9/0019 , A61K9/145 , A61K9/146 , A61K31/4166 , A61K47/10 , A61K47/16 , A61K47/186
摘要： Low volume safe for injection formulations of dantrolene yield significant advantages over the currently approved and marketed dantrolene for MH threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. Additionally, a safe for injection low volume formulation of dantrolene can be made widely available to non-anesthesiologist practitioners who have occasion to use dantrolene intravenously in the treatment of other potentially life threatening conditions, including in the field. The low volume, safe for injection formulations of dantrolene, as well as other formulations of dantrolene, have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：低剂量安非他酮注射剂配方，与目前批准和上市的丹曲林相比，具有威胁麻醉危险的MH。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重建过程中。另外，可以广泛使用非麻醉医师从事静脉内使用丹曲罗治疗其他潜在危及生命的疾病，包括在现场的非麻醉医师。对于预防和治疗泵头以及其他神经系统，认知和运动功能障碍，医源性或创伤性诱发的情况，丹那罗林的低体积，安全注射剂型以及其他丹曲林制剂具有显着优点。改变的血液流量，包括涉及CPB或相关手术的手术过程中发生的血流量以及在医源性或疾病引起的非正常体温发作期间发生的血流量。

7. 发明申请

WO2005034872A2 DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS 审中-公开
标题翻译：基于反相液相材料的药物递送车辆
公开(公告)号：WO2005034872A2
公开(公告)日：2005-04-21
申请号：PCT/US2004/033193
申请日：2004-10-08
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M. , CAMERANSI, Benjamin, G. Jr.
IPC分类号： A61K
CPC分类号： C09K19/02 , A61K9/1274
摘要： Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound. The invention also contemplates drug formulations containing reversed hexagonal and reversed cubic phases that can be applied to significantly increase the duration of action of the drug and/or provide the same duration and efficiency at a significantly lower dose.
摘要翻译：提供了包含设置在其内的活性物质的反相立方相或反六方相材料的未涂覆颗粒。未涂覆的颗粒具有足以使其稳定在液体分散中的离子电荷，例如，极性溶剂。设置在颗粒内的活性物质可以是例如药物或营养化合物。本发明还考虑了含有反向六方晶和反相立方相的药物制剂，其可用于显着增加药物作用的持续时间和/或以显着较低的剂量提供相同的持续时间和效力。

8. 发明申请

WO2003106168A1 COATED PARTICLES, METHODS OF MAKING AND USING 审中-公开
标题翻译：包衣颗粒，制造和使用方法
公开(公告)号：WO2003106168A1
公开(公告)日：2003-12-24
申请号：PCT/US2002/018654
申请日：2002-06-13
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M.
IPC分类号： B32B15/04
CPC分类号： A01N25/26 , A61K9/1274 , B01J13/02 , B82Y5/00 , Y10T428/2984 , Y10T428/2985 , Y10T428/2989
摘要： A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least one nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material.
摘要翻译：涂覆有非纤维材料如非晶体结晶材料，非平板非晶材料或非平板半结晶材料的颗粒包括具有至少一个纳米结构液相或至少一个纳米结构液晶相或两者的组合用于递送活性剂如药物，营养物，农药等。涂覆的颗粒可以通过各种不同的技术制造，其中外部涂层是非水性材料，例如非平板结晶材料，非层状无定形材料或非平板半结晶材料。

9. 发明申请

WO2003000236A1 PARTICLES WITH IMPROVED SOLUBILIZATION CAPACITY 审中-公开
标题翻译：具有改善溶解能力的颗粒
公开(公告)号：WO2003000236A1
公开(公告)日：2003-01-03
申请号：PCT/US2002/019623
申请日：2002-06-21
申请人： LYOTROPIC THERAPEUTICS, INC
发明人： ANDERSON, David, M.
IPC分类号： A61K9/14
CPC分类号： A61K9/1274 , A61K9/1075 , A61K36/00 , Y10T428/2989 , Y10T428/31544 , A61K2300/00
摘要： A particle is disclosed that comprises a first volume of hydrophobe-rich material with tunable dissolution and solubilization characteristics and a distinct second volume of nanostructural nonlamellar liquid crystalline material, said second volume containing said first domain and being capable of being in equilibrium with said first volume. Preferably, the nanostructured nonlamellar liquid crystalline material is capable of being in equilibrium with a polar solvent or a water-immiscible solvent or both.
摘要翻译：公开了一种颗粒，其包含具有可调溶解和溶解特性的第一体积的富含疏水物的材料和不同的第二体积的纳米结构非水性液晶材料，所述第二体积包含所述第一结构域并且能够与所述第一体积平衡。优选地，纳米结构非水性液晶材料能够与极性溶剂或与水不混溶的溶剂或两者均衡。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式